Rallybio Corp (RLYB): Price and Financial Metrics

Rallybio Corp (RLYB): $1.02

0.01 (+0.99%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add RLYB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#167 of 336

in industry

RLYB Price/Volume Stats

Current price $1.02 52-week high $4.20
Prev. close $1.01 52-week low $0.96
Day low $1.01 Volume 24,300
Day high $1.07 Avg. volume 589,841
50-day MA $1.10 Dividend yield N/A
200-day MA $1.46 Market Cap 42.32M

RLYB Stock Price Chart Interactive Chart >


Rallybio Corp (RLYB) Company Bio


Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.


RLYB Latest News Stream


Event/Time News Detail
Loading, please wait...

RLYB Latest Social Stream


Loading social stream, please wait...

View Full RLYB Social Stream

RLYB Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!